Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Thrombocythemia, Essential 2Polycythemia Vera 2Primary Myelofibrosis 1Melanoma 1Infections 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

peginterferon alfa-2a 2liposomal amphotericin B 2anagrelide 2Hydroxyurea 2Early Intervention, Educational 2Aspirin 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2peginterferon alfa-2b 1bomedemstat 1Pharmacogenomic Testing 1Ondansetron 1N(4)-oleylcytosine arabinoside 1Morphine 1Ketamine 1Hypericum extract LI 160 1Fentanyl 1Dextromethorphan 1Dalteparin 1Caspofungin 1Asian ginseng 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Thrombocythemia, Essential × peginterferon alfa-2a × Clear all
NCT01387763 2022-04-27

DALIAH

Odense University Hospital

Phase 3 Completed
202 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01259856 2019-04-30

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Icahn School of Medicine at Mount Sinai

Phase 3 Completed
168 enrolled 16 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡